The Role of Vedolizumab and Risankizumab in CD : comparemela

Anita Afzali, MD, David Hudesman, MD, Millie Long, and Miguel Regueiro, MD, discuss Vedolizumab and Risankizumab as treatments for Crohn’s Disease (CD).

Related Keywords

United States , Miguel Regueiro , David Hudesman , Anita Afzali , Crohns Disease , Cd , Vedolizumab , Risankizumab , Risk Stratification , Bio Naïve Population , Tumor Necrosis Factor ,